This is the third acquisition for the Edinburgh-based company since it was backed by Apposite Capital in January 2022.
Edinburgh-based speciality pharma business Kelso Pharma has acquired Milton Keynes-based pharma business, Alturix Holdings. Financial terms have not been disclosed.
In a statement, Kelso Pharma said that the acquisition would be complementary, with Kelso Pharma and Alturix “sharing a common philosophy” of supplying branded speciality medicines that provide patient benefits and a reduced cost burden to the NHS.
“This is a milestone acquisition for Kelso Pharma, doubling the size of our UK business and building a pharma company of scale. The Kelso platform is now positioned for further international growth as we seek to expand the markets for Alturix’s products, as well as further enhancing Kelso Pharma’s position as a partner of choice for other pharma businesses and innovative products,” said Kelso chief executive Tom Stratford.
Alturix has seven branded medicines in the therapeutic areas of the central nervous system, respiratory diseases and endocrinology. Kelso said that it intends to launch a further two pipeline products in the next 12 months which, added to its existing portfolio, will further expand the Kelso portfolio of 11 products in the UK market today.
Backed by Apposite Capital in January 2022, this is Kelso’s third acquisition since then and follows its takeover of Stirling Anglian Pharmaceuticals in January 2022 and Italian speciality pharma company Velit Biopharma in November 2023.
